Profile data is unavailable for this security.
About the company
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.
- Revenue in USD (TTM)25.49bn
- Net income in USD6.09bn
- Incorporated1901
- Employees35.00k
- LocationEli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
- Phone+1 (317) 276-2000
- Fax+1 (317) 276-3492
- Websitehttps://www.lilly.com/
Mergers & acquisitions
| Acquired company | LLY:NYQ since announced | Transaction value |
|---|---|---|
| Disarm Therapeutics Inc | 50.94% | 1.36bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen, Inc. | 25.16bn | 7.09bn | 139.48bn | 24.30k | 20.10 | 14.96 | 13.12 | 5.54 | 12.08 | 12.08 | 42.91 | 16.22 | 0.4052 | 1.59 | 5.34 | 1,035,556.00 | 11.41 | 11.20 | 14.24 | 13.36 | 75.62 | 80.70 | 28.16 | 33.20 | 1.34 | 9.45 | 0.7779 | 44.50 | 8.83 | 3.25 | -7.37 | 0.9197 | 0.467 | 15.16 |
| Bristol-Myers Squibb Co | 42.81bn | -6.22bn | 150.36bn | 30.25k | -- | 4.00 | 32.90 | 3.51 | -2.78 | -2.78 | 18.88 | 16.86 | 0.3542 | 4.17 | 5.95 | 1,415,207.00 | -5.13 | 2.55 | -6.05 | 3.19 | 76.66 | 72.44 | -14.48 | 5.97 | 1.45 | -- | 0.5513 | 192.95 | 62.62 | 20.75 | -362.14 | -- | -1.69 | 3.99 |
| Merck & Co., Inc. | 48.02bn | 7.03bn | 193.12bn | 74.00k | 27.57 | 7.17 | 17.91 | 4.02 | 2.77 | 2.77 | 18.93 | 10.64 | 0.5464 | 2.53 | 5.85 | 648,891.90 | 8.02 | 7.26 | 11.21 | 9.47 | 67.68 | 69.56 | 14.68 | 14.95 | 0.7779 | -- | 0.5362 | 85.46 | 2.46 | 3.97 | -29.05 | 9.73 | 29.56 | 6.62 |
| AbbVie Inc | 50.20bn | 5.08bn | 203.86bn | 48.00k | 40.76 | 14.86 | 15.33 | 4.06 | 2.83 | 2.83 | 28.78 | 7.76 | 0.4154 | 6.89 | 6.29 | 1,067,979.00 | 4.28 | 7.73 | 5.35 | 9.72 | 64.86 | 73.81 | 10.29 | 18.07 | 0.7292 | 5.19 | 0.8617 | 97.15 | 37.69 | 14.91 | -41.90 | -2.40 | 8.45 | 18.50 |
| Eli Lilly And Co | 25.49bn | 6.09bn | 214.91bn | 35.00k | 33.56 | 31.15 | 28.68 | 8.43 | 6.68 | 6.68 | 27.94 | 7.19 | 0.5796 | 1.82 | 4.76 | 728,160.00 | 13.86 | 10.28 | 19.25 | 14.54 | 75.88 | 77.19 | 23.91 | 19.52 | 1.10 | 233.32 | 0.6954 | 56.06 | 9.95 | 4.22 | 33.55 | 20.79 | 4.53 | 8.16 |
| Pfizer Inc. | 46.41bn | 9.40bn | 224.75bn | 78.50k | 24.06 | 3.27 | 15.80 | 4.84 | 1.67 | 1.97 | 8.32 | 12.27 | 0.2855 | 0.4933 | 4.70 | 591,172.00 | 5.80 | 4.81 | 7.15 | 5.96 | 22.43 | 78.95 | 20.34 | 17.45 | 1.16 | -- | 0.3657 | 100.53 | 1.79 | -3.02 | -33.57 | 0.1092 | 13.28 | 6.30 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2021 | 65.66m | 6.85% |
| PNC Bank, NA (Investment Management)as of 31 Mar 2021 | 51.60m | 5.38% |
| BlackRock Fund Advisorsas of 31 Mar 2021 | 37.80m | 3.94% |
| PRIMECAP Management Co.as of 31 Mar 2021 | 35.38m | 3.69% |
| SSgA Funds Management, Inc.as of 31 Mar 2021 | 32.51m | 3.39% |
| Wellington Management Co. LLPas of 31 Mar 2021 | 31.79m | 3.32% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2021 | 28.52m | 2.97% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2021 | 26.16m | 2.73% |
| State Farm Investment Management Corp.as of 31 Mar 2021 | 18.62m | 1.94% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2021 | 14.60m | 1.52% |
